Genelux Investor Presentation Deck

Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance GENELUX Pro-therapeutic gene expression Positive regulation of T-cell activating and trafficking Expression profiles correlated to better prognosis in cancer patients Promotion of sensitization/ response to chemotherapy Olvi-Vec-Induced Hot Tumor ABSENCE OF EFFECTOR T CELLS FIBROBLAST GSH 932932 cystine cysteine High GSH cystine Platinum resistant IFNY cystine cisplatin 0.0 000 CANCER PRESENCE OF EFFECTOR T CELLS APR --00 cysteine GG XXXX Low GSH GSH Platinum sensitive GOTS 78000 anscription- 93 GOTS Chemotherapy synergy Immunogenic cell death Depletion of suppressor cells Increase susceptibility to cytotoxic T-lymphocytes 7

View entire presentation